PhytoHealth Corporation

Taipei

OncologymicrobiomeFiled/Approved

What changed

Phase II trial registered: A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)

6w agoTrial registeredJun 4, 2026Source filing (opens the source filing in a new tab)

Momentum

93no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

72 pre-ticker oncology companies at Filed/Approved

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE1/PHASE2 registered
Oct 1, 2026
MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus) · NOT_YET_RECRUITING · sponsor: George Washington University · A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)
ClinicalTrials.gov · NCT06792500 (opens the source filing in a new tab)
Grant
P20 · $475k · non-dilutive
May 15, 2026
UNIVERSITY OF OKLAHOMA · PI CHEN, WEI R. · NIGMS · award ends Jan 31, 2031 · Oklahoma Center of ImmunoEngineering (OCIE)
NIH RePORTER · NIH RePORTER 11269423 (opens the source filing in a new tab)
Grant
P20 · $2.5M · non-dilutive
May 15, 2026
UNIVERSITY OF OKLAHOMA · PI CHEN, WEI R. · NIGMS · award ends Jan 31, 2031 · Oklahoma Center of ImmunoEngineering (OCIE)
NIH RePORTER · NIH RePORTER 11269422 (opens the source filing in a new tab)
Grant
P20 · $420k · non-dilutive
May 15, 2026
UNIVERSITY OF OKLAHOMA · PI CHEN, WEI R. · NIGMS · award ends Jan 31, 2031 · Alteration and Renovation (A&R) Project
NIH RePORTER · NIH RePORTER 11269430 (opens the source filing in a new tab)
Trial
NA registered
Aug 7, 2025
Adverse Event, Peritoneal Dialysis, Moderate-to-severe Pruritus, Chronic Kidney Disease-associated Itch · RECRUITING · sponsor: Guangdong Provincial People's Hospital · Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis
ClinicalTrials.gov · NCT07098351 (opens the source filing in a new tab)
Trial
PHASE2 registered
May 17, 2023
Cancer-related Fatigue · RECRUITING · sponsor: PhytoHealth Corporation · PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients
ClinicalTrials.gov · NCT05440227 (opens the source filing in a new tab)
Trial
Study registered
Dec 27, 2021
Chronic Kidney Disease · RECRUITING · sponsor: Guangdong Provincial People's Hospital · A Real World, Multi-centric, Observational Registry Study of Chronic Kidney Diseases
ClinicalTrials.gov · NCT05188885 (opens the source filing in a new tab)
Trial
PHASE4 registered
Jul 30, 2020
CKD (Chronic Kidney Disease) Stage 5D · RECRUITING · sponsor: Guangdong Provincial People's Hospital · ASPIrin in Reducing Events in Dialysis ( ASPIRED )
ClinicalTrials.gov · NCT04381143 (opens the source filing in a new tab)
Trial
Study registered
May 1, 2020
IgA Nephropathy · RECRUITING · sponsor: Guangdong Provincial People's Hospital · Correlation of Microbiome and Metabonomics With IgA Nephropathy
ClinicalTrials.gov · NCT05190848 (opens the source filing in a new tab)
Trial
PHASE4 registered
Feb 1, 2018
Diabetes Mellitus, Type 2, Adverse Event, Blood Pressure, Prehypertension, Cardiovascular Risk Factor · RECRUITING · sponsor: XueQing Yu · Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes
ClinicalTrials.gov · NCT03264352 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 76%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75principal investigator CHEN, WEI R. is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75principal investigator CHEN, WEI R. is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75principal investigator CHEN, WEI R. is named on this company's filings
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Investigators

The principal investigators named on the grants below. Each links to their federal grant record and every other company traced to their work.

Wei R. Chen

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)
6w agoTrial registeredSource (opens the source filing in a new tab)
NIH P20 · $0.5M · Oklahoma Center of ImmunoEngineering (OCIE)
2mo agoNew grantSource (opens the source filing in a new tab)
NIH P20 · $2.5M · Oklahoma Center of ImmunoEngineering (OCIE)
2mo agoNew grantSource (opens the source filing in a new tab)
NIH P20 · $0.4M · Alteration and Renovation (A&R) Project
2mo agoNew grantSource (opens the source filing in a new tab)
Study registered, no phase assigned: A Real World, Multi-centric, Observational Registry Study of Chronic Kidney Diseases
6mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Real World, Multi-centric, Observational Registry Study of Chronic Kidney Diseases
6mo agoTrial recruitingSource (opens the source filing in a new tab)
Filed/Approved trial registered: ASPIrin in Reducing Events in Dialysis ( ASPIRED )
8mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: ASPIrin in Reducing Events in Dialysis ( ASPIRED )
8mo agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis
10mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis
10mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients
Jun 2025Trial registeredSource (opens the source filing in a new tab)
Trial now recruiting: PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients
Jun 2025Trial recruitingSource (opens the source filing in a new tab)
Filed/Approved trial registered: Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes
Mar 2025Trial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes
Mar 2025Trial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Correlation of Microbiome and Metabonomics With IgA Nephropathy
Mar 2025Trial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Correlation of Microbiome and Metabonomics With IgA Nephropathy
Mar 2025Trial recruitingSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Peer position

Grant to raise

PHASE1/PHASE2 registered

P20 · $475k · non-dilutive

P20 · $2.5M · non-dilutive

P20 · $420k · non-dilutive

NA registered

PHASE2 registered

Study registered

PHASE4 registered

Study registered

PHASE4 registered